Study of DS-7300a in Participants With Advanced Solid Malignant Tumors
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study is in one single group of participants with advanced solid tumors who have not
been cured by other treatments. It is the first time the drug will be used in humans, and
will be in two parts.
The primary purpose of the parts are:
- Dose Escalation Part: To evaluate the safety and tolerability and to determine the
maximum tolerated dose and the recommended dose for expansion of DS-7300a.
- Dose Expansion Part: To investigate the safety, tolerability and antitumor activity of
DS-7300a when administered as a single agent.
This study is expected to last approximately 5 years from the time the first participant is
enrolled to the time the last participant is off the study.
The number of treatment cycles is not fixed in this study. Participants who continue to
benefit from the study treatment may continue, unless:
- they withdraw
- their disease gets worse
- they experience unacceptable side effects.